My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Terns Pharmaceuticals, Inc. - Common Stock (NQ:TERN)

37.79 +0.04 (+0.11%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Terns Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Should You Invest in This Under-the-Radar Weight Loss Stock? ↗

September 15, 2024

Getting in on the ground floor sounds like a great idea, but not if the building ends up crumbling.

Via The Motley Fool

1 New Weight Loss Drug Stock to Buy Now With $1,000 and Hold for 5 Years or More ↗

September 14, 2024

This biotech's data suggests that it could have an advantage in its target market.

Via The Motley Fool

Calavo Growers Posts Better-Than-Expected Earnings, Joins Tesla, Oracle, Mission Produce And Other Big Stocks Moving Higher On Tuesday ↗

September 10, 2024

Via Benzinga

Oracle To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

September 10, 2024

Via Benzinga

Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday ↗

September 09, 2024

Via Benzinga

Top 2 Health Care Stocks That May Collapse This Quarter ↗

September 09, 2024

Via Benzinga

TERN Stock Earnings: Terns Pharma Meets EPS for Q4 2023 ↗

March 14, 2024

TERN stock results show that Terns Pharma met analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

Terns Pharmaceuticals' Oral GLP-1 Reaches Phase 1 Finish Line With Encouraging Weight Loss Data After One Month ↗

September 09, 2024

Terns Pharmaceuticals announced promising Phase 1 trial results for TERN-601, showing significant weight loss in obese and overweight adults, with up to 4.9% placebo-adjusted mean weight loss at the...

Via Benzinga

The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race ↗

August 29, 2024

The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots.

Via Investor's Business Daily

TERN Stock Earnings: Terns Pharma Beats EPS for Q2 2024 ↗

August 05, 2024

TERN stock results show that Terns Pharma beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

3 Biotech Stocks That Could Have Investors Grinning Soon ↗

August 02, 2024

Biotech stocks are a high risk, high reward investment and these three biotechs offer significant upside potential.

Via InvestorPlace

Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs? ↗

July 20, 2024

At least one of the pair has a credible shot at finding a home in the market.

Via The Motley Fool

Recap: Terns Pharma Q3 Earnings ↗

November 14, 2023

Via Benzinga

12 Analysts Have This to Say About Terns Pharma ↗

July 26, 2023

Via Benzinga

EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players' ↗

July 18, 2024

Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry.

Via Benzinga

Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

July 11, 2024

Via Benzinga

Methode Electronics Posts Strong Sales, Joins QuantumScape, Ribbon Communications And Other Big Stocks Moving Higher On Thursday ↗

July 11, 2024

Via Benzinga

TERN Stock Earnings: Terns Pharma Beats EPS for Q1 2024 ↗

May 13, 2024

TERN stock results show that Terns Pharma beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich ↗

March 25, 2024

Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom.

Via InvestorPlace

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

March 21, 2024

Via Benzinga

Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy? ↗

March 17, 2024

Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.

Via The Motley Fool

Top 5 Health Care Stocks That Are Ticking Portfolio Bombs ↗

December 05, 2023

As of Dec. 5, 2023, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Via Benzinga

Why Take-Two Interactive Software Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

February 09, 2024

Shares of Take-Two Interactive Software, Inc. (NASDAQ: TTWO) fell sharply during Friday’s session following third-quarter results.

Via Benzinga

SAIC Reports Q3 Results, Joins Uber, Wallbox And Other Big Stocks Moving Higher On Monday ↗

December 04, 2023

U.S. stocks traded lower, with the Dow Jones index falling more than 100 points on Monday.

Via Benzinga

Topics Stocks

Why U Power Shares Are Trading Lower By Around 54%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

December 04, 2023

Shares of U Power Limited (NASDAQ: UCAR) shares moved lower during Monday’s session after the company announced pricing of registered follow-on offering of 10 million units at a purchase price of $1.20...

Via Benzinga

3 Biotechs Compete for the Same $108-Billion-Dollar Market. Are They a Buy? ↗

August 23, 2023

NASH treatments are projected to be one of the most sought-after indications in the coming years.

Via The Motley Fool

Looking for the Next Big Biopharma Stock? These 4 Letters Are 1 Big Clue Where to Find It ↗

August 23, 2023

NASH is a surprisingly common ailment, and the first treatments are on the way.

Via The Motley Fool

Global Payments To Rally Around 17%? Here Are 10 Other Analyst Forecasts For Thursday ↗

August 10, 2023

Keybanc cut the price target for i3 Verticals, Inc. (NASDAQ: IIIV) from $28 to $26. Keybanc analyst Josh Beck maintained an Overweight rating. i3 Verticals shares fell 2.9% to close at $22.76 on...

Via Benzinga

Terns Pharmaceuticals Is "Attractively Priced" Despite Pressure From Eli Lilly's Obesity Data, Analyst Says ↗

June 28, 2023

Tuesday, Terns Pharmaceuticals Inc (NASDAQ: TERN) shares lost more than 25% of their value due to investor pressure it faced after Eli Lilly And Co (NYSE: LLY) announced data from retatrutide that was...

Via Benzinga

Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

June 27, 2023

Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health.

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.